ABD and its predecessors have been registered with and inspected by the US Food & Drug Administration since 1976. Our original diaphragm pacing system received premarket approval status from the FDA immediately upon requirement in 1986, with the latest PMA supplement approved in November 2019. FDA premarket approval is required before Class III medical devices can be commercially distributed in the United States. The Avery Diaphragm Pacing System is the only device with such approval.
The premarket approval number for the Diaphragm Pacing System is P860026. The FDA Center for Devices and Radiological Health has assigned diaphragmatic/phrenic nerve stimulators the product code GZE under CFR 882.5830.
European Community (EU Countries, Switzerland and Norway)
Avery Biomedical Devices holds certificate number FM 547851 and operates a Quality Management System which complies with the requirements of ISO 13485: 2016 for the design and development, production and servicing of implanted diaphragm pacemaker systems.
The EC Declaration of Conformity is based on approved quality system and design examination by the Notified Body BSI Management Systems. The EU Authorized Representative is Advena Ltd.
United Kingdom (England, Wales, and Scotland)
The Avery Diaphragm Pacing System is registered with the UK Medicines & Healthcare products Regulatory Agency (MHRA). The UK Responsible Person (UKRP) is Advena Ltd.
The Avery Diaphragm Pacing System has been registered with the Administractión Nacional de Medicamentos Alimentos y Tecnologia Médica since June 2010.
The Avery Diaphragm Pacing System has been registered with the Israel Ministry of Health – Medical Technology, Information and Research Division (Medical Devices Department).
Our authorized representative is Lowenstein-Weinmann Medical Israel Ltd.
The Avery Diaphragm Pacing System has been registered with the Russian Ministry of Health since May 2010.
Our authorized representative in the Russian Federation is Edward Indilov.
The Avery Diaphragm Pacing System has been registered with Instituto Nacional de Vigilancia de Medicamentos y Alimentos since February 2009.
Our authorized representative in Colombia is Medihumana Colombia.